Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
about
Screening for prostate cancerProstate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based AnalysisPopulation screening for prostate cancer: an overview of available studies and meta-analysisActive surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis.How should prostate specific antigen be interpreted?Historical prostate cancer screening and treatment outcomes from a single institutionRisk perception and psychological morbidity in men at elevated risk for prostate cancerProstate-specific antigen screening can be beneficial to younger and at-risk men.Genetic correction of PSA values using sequence variants associated with PSA levels.Psychological Predictors of Prostate Cancer Screening Behaviors Among Men Over 50 Years of Age in Hamadan: Perceived Threat and Efficacy.Prostate cancer mortality in areas with high and low prostate cancer incidence.Prostate-specific antigen screening: proDiagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.The implementation of screening for prostate cancer.Informed prostate cancer risk-adjusted testing: a new paradigm.Ghrelin receptor as a novel imaging target for prostatic neoplasms.Treatment patterns among Canadian men diagnosed with localized low-risk prostate cancer.Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screeningPersonalized prostate cancer screening: improving PSA tests with genomic information.Characterization of prostate cancer cell progression in zebrafish xenograft model.Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue.Trends in prostate cancer survival in Spain: results from population-based cancer registries
P2860
Q24201690-9E031C25-B841-4521-9B11-8AB27B836992Q26781093-A50C849A-2F33-4C04-B12E-007D13B9B66CQ26829319-D19D6B5A-108C-4591-BF82-722CA186ACDBQ33855285-D60FD677-C905-4AF5-81B8-A9A0DAB776A8Q33935048-A67001BE-ACAC-4C13-8EB4-BA79C7237902Q34387852-C0C48D9A-AF8D-478C-BB52-24A7C5162F10Q35000853-877B235E-2B9E-4FCC-BA1B-63E4879BBDADQ35993964-8ADB9946-9587-472B-8BB2-A444040AAD61Q36170995-33F50B7D-2D79-4585-8D3F-D16F477C23B4Q36394622-C6DC4328-DFFB-4F06-B996-D4DECE5825B4Q36510711-B2210690-25C8-4E7F-90E0-D7B7184A3CE0Q36588082-82FF577A-4450-403F-86AD-A41A03905F7CQ37322274-ADCB7B18-4048-4842-BF6F-9E8C7F013897Q37696462-CACE8810-6351-43E9-A9A5-907ECEEB0AD2Q37707943-141A4BC7-CCB3-4E43-AE01-DD7A691F10D4Q37738370-A8602749-7E3C-46FA-AA59-B64E8C88CDDEQ37777325-933B19B5-FF3A-4709-92A1-7986EAEB9367Q38063556-94CBD6FD-F33D-459B-8891-79FB76693FD2Q39473579-39BD7523-8ECC-44C7-B1E4-859C9B956D57Q40159802-1A9A7083-F30C-476C-A500-95416D727B5BQ41609967-53B734AB-3C1B-469B-9631-86A6B907EBB4Q41833638-76834DDC-7967-4EBD-B975-2D89C1DED9DAQ45978317-4331B2DD-149D-4CE3-BB54-BFB693EBB2E1Q47426582-C4AF8490-EEAF-444F-84A9-C18203F956DDQ51731326-47E1D22E-820D-4E34-AA86-1C85FA13079BQ57252067-7B513B65-366E-4499-87D5-14106516F0E1
P2860
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prostate cancer mortality in s ...... imating the screening benefit.
@ast
Prostate cancer mortality in s ...... imating the screening benefit.
@en
Prostate cancer mortality in s ...... imating the screening benefit.
@nl
type
label
Prostate cancer mortality in s ...... imating the screening benefit.
@ast
Prostate cancer mortality in s ...... imating the screening benefit.
@en
Prostate cancer mortality in s ...... imating the screening benefit.
@nl
prefLabel
Prostate cancer mortality in s ...... imating the screening benefit.
@ast
Prostate cancer mortality in s ...... imating the screening benefit.
@en
Prostate cancer mortality in s ...... imating the screening benefit.
@nl
P2093
P1476
Prostate cancer mortality in s ...... timating the screening benefit
@en
P2093
Amanda Black
Anna Gavin
Chris H Bangma
David Connolly
Fritz H Schröder
Pim J van Leeuwen
P304
P356
10.1016/J.EJCA.2009.09.008
P577
2009-10-03T00:00:00Z